Prognosis of Patients With Relapsed/Refractory Hodgkin Lymphoma Treated With IGEV Induction Therapy Before HDCT With AHSCT (IIL-ProHLRec)

Fondazione Italiana Linfomi - ETS

Status: Completed

Conditions: Hodgkin's Lymphoma

Study type: Observational

Funder types: Other

Identifiers

NCT01478191

30

IIL-ProHLRec

Details and patient eligibility

About

This is a retrospective analysis of a homogeneous cohort of patients with relapsed/refractory HL that received IGEV scheme as induction therapy to HDCT and AHSCT for reassess the most common prognostic factors and try to identify a prognostic score with clinical and therapeutic relevance by using 6 clinical tools:

1. B symptoms(yes/no)
2. relapse in previously irradiated areas(yes/no)
3. Ann Arbor Stage (III/IV vs I/II)
4. disease status at accrual (refractory vs relapsed)
5. Early relapse within 12 months of Complete Response (CR) versus late relapse after Complete Response (CR) lasting > l2 months",
6. extranodal involvement (yes/no).

Enrollment: 495 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Patient with a history of classical HL relapsed/refractory which received IGEV regimen as induction therapy before high dose chemotherapy with AHSCT
• Age >18 years
• Patients with relapsed/refractory disease after standard treatments (chemotherapy +/- radiotherapy) before IGEV induction regimen. (Relapsed = disease relapse after CR.

Refractory = non CR with last chemotherapy line, or progression during last treatment, or disease progression within three months from previous treatment completion).

• Availability of clinical data, laboratory values and CT scan results of patients enrolled, performed from diagnosis to the last follow-up
• Patient scheduled to receive three or four IGEV cycles as pretransplantation induction regimen.
• First IGEV course started before December 31st 2007
• Assessment of tumor response by Cheson 1999 criteria 11

Exclusion criteria

• NONE